Phillips & Cohen Evidentiary Data Scientist George Collins

Affiliates of Kaiser Permanente, one of the nation’s largest integrated healthcare providers, reached a significant $581 million settlement with the federal government last month to resolve multiple whistleblower lawsuits. These cases alleged that the companies engaged in widespread "risk adjustment" fraud and other forms of misconduct within the Medicare Advantage program, a critical component of the federal healthcare system. The landmark agreement highlights the enduring power of the False Claims Act’s qui tam provisions and the increasingly crucial role of specialized legal and data science expertise in combating complex financial malfeasance in the healthcare sector.

Unraveling the Allegations: The Mechanics of Medicare Advantage Fraud

The core of the allegations revolved around the Medicare Advantage (MA) program, also known as Medicare Part C. Under this program, the Centers for Medicare & Medicaid Services (CMS) contracts with private insurance companies, like Kaiser’s various plans, to provide healthcare services to Medicare beneficiaries. Instead of directly paying for each service, the government pays these MA plans a fixed fee per member, designed to cover their medical needs. This fee, however, is not static; it is "risk adjusted." This means the payment amount is calculated based on each member’s health status, age, and other demographic factors that are likely to influence their need for medical services. Healthier, lower-risk individuals generate lower payments for the plans, while sicker, higher-risk individuals result in increased payments to compensate the insurers for the anticipated higher costs of their care.

The alleged fraud centered on the manipulation of diagnostic codes. Medicare Advantage payments are significantly influenced by the diagnostic codes submitted by health plans, which are meant to accurately reflect the health conditions diagnosed in their beneficiaries throughout the year. When beneficiaries are diagnosed with certain serious or chronic health conditions, the government correspondingly increases its payments to the insurers to account for the higher expected healthcare expenditures. The whistleblower lawsuits contended that Kaiser Permanente affiliates systematically submitted inaccurate or inflated diagnostic codes, effectively making patients appear sicker than they actually were. This practice, often referred to as "risk adjustment fraud," directly led to the government making substantially higher payments to the defendants than they were legitimately entitled to receive.

One of the key examples cited in the Phillips & Cohen lawsuit, filed in 2014, involved patients with a prior history of cancer being frequently miscoded as having active cancer. Such miscoding would dramatically increase the government’s payments to the MA plans, despite the fact that the patients were not actively undergoing treatment for cancer. The complaint further alleged that the companies failed to implement appropriate corrective actions, which would have necessitated refunding past overpayments and adjusting their revenue expectations moving forward. This failure to rectify identified discrepancies compounded the alleged misconduct, transforming what might have been isolated errors into a pattern of systemic fraud.

The Genesis of the Lawsuit: Whistleblowers and the False Claims Act

The journey to this significant settlement began with the courage of whistleblowers, individuals who stepped forward to expose the alleged wrongdoing. The lawsuit against Kaiser Permanente affiliates was brought under the qui tam provisions of the False Claims Act (FCA), a powerful federal statute designed to combat fraud against the government. The FCA allows private citizens, known as "relators," to file lawsuits on behalf of the government and share in any financial recovery. This mechanism incentivizes individuals with internal knowledge of fraud to come forward, acting as private attorneys general.

One of these pivotal lawsuits was initiated in 2014 by the law firm Phillips & Cohen on behalf of a whistleblower client. George Collins, Senior Counsel and Evidentiary Data Scientist with Phillips & Cohen, played a crucial role in the litigation. Reflecting on the outcome, Collins emphasized the broader implications: "This remarkable outcome highlights the scope and significance of health care fraud and the importance of whistleblowers in recovering money that should be going to patient care and affordability instead of the pockets of health care companies." His statement underscores the dual impact of such settlements: not only recovering taxpayer funds but also reinforcing ethical conduct within the healthcare industry.

A Deep Dive into the Chronology and Legal Process

While the precise internal timeline leading to the alleged fraud remains undisclosed, the legal battle began with the filing of the qui tam lawsuit in 2014. Under the False Claims Act, these cases are initially filed under seal, allowing the Department of Justice time to investigate the allegations. During this period, the government can decide whether to intervene and take over the prosecution of the case. In the Kaiser Permanente matter, the government ultimately chose to join the case, signaling its confidence in the merits of the whistleblowers’ claims and the evidence presented. Government intervention often strengthens a case, bringing the full investigative and prosecutorial resources of the federal government to bear.

Following intervention, the case typically moves through various stages of litigation, including discovery, motions, and potentially trial. However, many False Claims Act cases, particularly those involving complex data analysis and substantial alleged damages, are resolved through settlement. The $581 million agreement reached "last month" indicates a culmination of years of investigation, negotiation, and legal strategizing since the 2014 filing. This settlement avoids a lengthy and costly trial for all parties involved, while still holding the companies accountable for the alleged misconduct.

The Rise of the Evidentiary Data Scientist: George Collins’ Method

The complexity of modern fraud, particularly in data-rich environments like healthcare, necessitates innovative investigative approaches. George Collins exemplifies this evolution in legal practice. As an "evidentiary data scientist," his practice is uniquely focused on two types of whistleblower cases: "data-centric" cases, where large, intricate datasets serve as primary evidence of fraud, and "software-centric" cases, where software itself is either the instrument or the subject of fraudulent activity.

Collins’ background is deeply rooted in computer programming, algorithms, and data analytics. He is fluent in multiple programming languages and employs a diverse array of analytical methods, including machine learning, natural language processing (NLP), and complex systems modeling. This specialized toolkit enables him to address the intricate challenges that arise at every stage of a case, from initial investigation to litigation.

In an interview, Collins clarified the distinction between his work and traditional e-discovery. While e-discovery typically deals with vast volumes of unstructured digital documents, such as emails and scanned files, Collins focuses on "structured data." This can involve petabytes of information, such as an entire company’s internal database, fifteen years of point-of-sale transactions from a national pharmacy, or comprehensive supply chain data from a government contractor. His expertise lies in sifting through billions of lines of structured data, often without clear documentation, to identify patterns indicative of fraud. He emphasizes the value of internal data analysis: "Traditionally this work has been outsourced to external consulting companies. What my colleagues and I try to do is think of that data as another source of evidence, not just in terms of a damages analysis, but also as central evidence often of liability in the case itself, structure a legal strategy around it, consider how it relates to every other piece of data in the case."

Collins also offered a nuanced perspective on artificial intelligence (AI). He distinguishes between "machine learning," which he extensively uses as an outgrowth of classical statistics applied to computation at scale, and "generative AI." While machine learning is integral to his work for identifying precise patterns and anomalies in data, he finds limited application for generative AI in his specific practice of crafting extremely precise specifications for fraudulent patterns. His work demands exactitude and verifiable evidence, rather than plausible but potentially unverified generated content.

Collins’ track record underscores the effectiveness of his approach. In 2024, he was instrumental in securing a $90 million settlement against Humana, Inc. for allegedly submitting fraudulent bids for a Medicare Part D plan. He also contributed to a $108.75 million settlement with KBR for defrauding the United States Army in connection with supply contracts during the Iraq War. These cases highlight the broad applicability of his data-driven investigative methods across various sectors involving government contracts.

Broader Implications: Deterrence, Scale of Fraud, and Whistleblower Protection

The Kaiser Permanente settlement, along with other successful False Claims Act cases, raises critical questions about the deterrent impact on corporate misconduct. Collins believes these cases "are definitely having an impact," noting that "whole areas of fraud have been largely stamped out or at least it’s made it much harder to convince a group of people in a company to move forward with it." He observes that certain types of fraud are no longer prevalent because the industry has deemed them too risky due to increased enforcement. However, he also acknowledges that companies may simply "refine what they are doing or change its approach," suggesting a continuous cat-and-mouse game between fraudsters and enforcement.

The sheer scale of healthcare fraud in the United States remains a staggering concern. Estimates from experts like Harvard professor Malcolm Sparrow place annual losses to healthcare fraud between $100 billion and $500 billion. Collins agrees that this figure, or even a higher one, is "absolutely possible," underscoring that the amount of undetected fraud far outweighs what is currently brought to light. This reinforces the critical need for continued vigilance and robust enforcement mechanisms like the False Claims Act.

The success of qui tam litigation hinges on the quality and courage of whistleblowers. Collins elaborated on the indicators of a strong whistleblower case:

• Internal Knowledge: Whistleblowers who possess knowledge about internal company decisions, the rationale behind them, and any concerns raised about their legality are invaluable.
• Awareness of Intent: Information about internal attempts to override questionable decisions or the company’s awareness of the illegality of its practices is crucial for proving fraud, which requires a higher standard than mere negligence.
• Legitimate Access to Data: While whistleblowers should never root around in company systems, those who have legitimately accessed relevant data in the ordinary course of their work can provide powerful evidence.
• Motivation: Often, whistleblowers are not merely disgruntled employees but individuals who believe in their company’s mission and are dismayed when it fails to live up to its ethical obligations, especially when patient care or public funds are at stake.

Collins also shed light on the nuances of government intervention in FCA cases. While government intervention, as occurred in the Kaiser case, is often seen as a strong endorsement, a "declination" (when the government chooses not to formally join a case) is not necessarily a sign of weakness. Declinations can occur due to resource constraints, or because the government has confidence in the relator’s law firm to pursue the case independently. Even in declined cases, the government often remains closely involved, as its interests are ultimately at stake. This flexibility ensures that meritorious cases can still proceed, even if the government’s immediate resources are directed elsewhere.

Kaiser Permanente’s Post-Settlement Posture (Inferred)

While Kaiser Permanente’s specific statements regarding the settlement were not detailed in the original report, it is common for corporations in such situations to issue statements affirming their commitment to compliance, cooperation with government authorities, and the implementation of measures to prevent future occurrences. Settlements typically include a "no admission of wrongdoing" clause, allowing the company to resolve the matter without formally acknowledging liability, while still paying a substantial sum. The payment of $581 million, however, signals a significant acknowledgment of the gravity of the allegations and the strength of the evidence compiled by the whistleblowers and the government. Such settlements invariably lead to internal reviews of compliance programs, diagnostic coding practices, and data integrity protocols to mitigate future risks and restore public trust.

A Continuing Battle for Integrity in Healthcare

The Kaiser Permanente settlement serves as a stark reminder of the persistent challenge of healthcare fraud and the immense financial drain it imposes on federal programs like Medicare Advantage. The resolution of these cases, driven by diligent whistleblowers and sophisticated legal and data analysis, reinforces the integrity of the False Claims Act as a primary tool for accountability. As healthcare systems grow more complex and data-driven, the synergy between legal expertise and advanced data science, as exemplified by George Collins, will become even more indispensable in safeguarding taxpayer dollars and ensuring that healthcare resources are directed towards patient care, not corporate misconduct. The ongoing battle against fraud remains a critical endeavor to protect the public purse and uphold the ethical foundations of the nation’s healthcare infrastructure.